AVEO presents tivozanib Stage 2 study results at ESMO Congress AVEO Pharmaceuticals, Inc. , a biopharmaceutical business focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported outcomes from its Phase 2 research analyzing tivozanib for the treating advanced renal cell carcinoma were presented at the 35th European Culture for Medical Oncology Congress in Milan, Italy. ESMO may be the leading European oncology professional firm, focused on advancing the specialty of medical oncology and promoting a multidisciplinary method of cancer treatment and treatment.D., Sc.M., chief medical officer at AVEO.‘There is usually concern that the malarial vectors have become resistant to the entire class of insecticides the WHO approves,’ he said. ‘Resistance is the ‘first warning indication you need to take necessary methods to ensure that the few insecticides we’ve. Will be effective,’ said Sam Awolola, a scientist with Nigerian Institute of Medical Analysis,’ AFP reports. ‘With a government target to roll out 62 million bednets in Nigeria by the end of next year, there are fears fake items might filter in to the country previously notorious for fake pharmaceutical drugs. ‘Instead of a net being 100 % impregnated they might be 50 % impregnated, and which means the mosquitoes obtain half a dosage, survive and pass the gene to the next resistance and generation builds,’ said Awolola, adding ‘however we’ve a very porous market in Nigeria” .